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Since the pioneering" studies of Everett, Sawyer and Markee (I) it has been 
~enerally accepted that the central nervous system (CNS) regulates the secretion of 
the pituitary gonadotropins, luteinJzinff hormone (LH) and follicle stimulatin~ hormone 
(FSH). Ilowever, great gaps still exist in our understandinl~ of the neural mechanisms 
that regulate the secretion of these hormones. The purpose of this review is to 
provide the reader with a concise overview of this topic. Gaps, inconsistencies and 
future directions of this area of research are also presented. 
ANATOMICAL CONSIDERATIONS 
The central nervous system communicates with the anterior pituitary throu~,h a 
vascular route. Specialized neurons within the preoptico-hypothalamus (a neural re~ion 
located in the ventral portion of the dJencephalon) synthesize the decapeptide, 
luteinizing hormone releasing, hormone (LHRH) (2-4). LHRH is secreted from neuronal 
terminals into a specialized capillary network that surrounds the median eminence, a 
circumventricular or~,an. Followin~ entry into the pituitary portal vAsculature, this 
neurohormone is delivered to the anterior pituitary (5) where it interacts with pituitary 
gonadotropes and stimulates the synthesis and release of LH and FSH. Since LH and 
FSH are secreted in pulses, it is assumed that each ~'onadotropin pulse occurs as a 
result of a pulsatile discharR'e of hypothalamic LHRH (6). Thus, an important feature 
of communication between the CNS and the pituitary is the pattern with which it occurs. 
LHRH PULSE MODES 
Indeed, the pituitary gland responds onl~ to pulsatile modes of LHRH delivery 
and exhibits the phenomenon of down-regulation when exposed to a "square-wave" of 
LHRH (6). Hypogonadotropic hypogonadism produced in female rhesus monkeys by 
placement of extensive radiofrequencv lesions in the medial basal hypothalamus (MAR) 
may be reversed and ovulatory cyclicity restored by pulsatile but not continuous infusion 
of LHRN (6,7). In addition to an absolute requirement for a pulsatile mode of LHRH 
exposure, pituitary reponses differ depending" upon I,HRH pulse frequency. Slower 
LHRR pulse frequencies elicit a g'reater FSH/LH release ratio whereas increased 
frequencies result in a greater LH/FSH ratio (6,8). Alterations in LNRH pulse frequency 
have been proposed as the mechanism by which a sinl~le releasing, hormone ~,overns the 
release of two pituitary gonadotropins (8). In addition, pulse amplitude and duration 
of LHRH may also be an important means of information transmission (9). Thus, in 
our developing neuroendocrine model, we envision LHRH neurons, located in the ventral 
portion of the brain, to discharR'e quanta of LHRH in a pulsatile fashion to stimulate 
gonadotropin synthesis and release. The frequency and amplitude of these pulses 
affects the type of pituitary response. 
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What dictates the frequency of hypothalamie LHRH discharges? The existing, 
endocrine milieu appears to be an important factor. LHRH pulse frequency varies 
during the ovulatory cycle (I0). Gonadectomy increases LHRH pulse releases, which 
result in elevated levels of LHRH in pituitary stalk blood and a rise in perioheral 
gonadotropin concentrations (IlL Replacement of gonadal hormones to castrates slows 
LHRH pulse frequency, reduces the rate of pituitary ~onadotropin secretion and results 
in a reduction of circulating' LH and FSH levels (II). Prolonged exposure to high 
physiologic levels of estradiol reverses this inhibitory effect upon hypothalamic LHRH 
pulse frequency and results in a surge of ~'onadotropins (II). Alteration in LHRH pulse 
frequency induced by the hormonal milieu serves as a prime example of neuroendocrine 
transduction. Circulating levels of gonadal steroid hormones interact with steroid- 
sensitive neural tissue (12). As a result of steroid-neuronal interactions, firin~ rates 
of certain hypothalamic neuronal systems are affected (13,14). Transduction of 
endocrine (gonadal steroids) to neurophysiological (firin~ rates of estradiol-sensitive 
tissue) signals results in an alteration in LHRH pulse frequencv and, therefore, pituitary 
gonadotropin secretion. 
How and where does the transduction of steroidal to neurophysiolo¢ical information 
occur? Distinct neuroanatomical regions p lay  important roles in regulation of 
gonadotropin release. Studies that employ electrical recording, neural disconnections 
or lesions, and electrical and electrochemical stimulations have clearly implicated a 
broad expanse of neuronal tissue within the preoptico-hyDothalamus as being" critically 
involved in the transduction phenomenon (15,16). The neuroanatomical boundaries of 
this area are: the rostral aspect of the preoptic area (above the optic chiasm) throu~,h 
the hypothalamus and funnellin~ caudally toward the median eminence (above the 
pituitary stalk). The majority of LHRH-producin¢. cell bodies are located within the 
preoptic area (2-4,15). Ablation of these cell bodies or placement of a surgical cut 
between the preoptic area and the medial basal hypothalamus blocks the occurrence 
of the midcycle ~onadotropin surge but not steroid-induced reductions in ~'onadotropin 
secretion. This information suggests that distinct areas of the preoptico-hvpothalamus 
regulate different ~onadotropic responses to ~,onadal steroids. Rostral areas appear 
to control positive feedback actions (i.e., the midcycle ~onadotropin sure, e) whereas 
steroid-modulated gonadotropin negative feedback is focused within the basal 
hypothalamus (15,16). Thus, the frequency of LHRH release into the pituitary portal 
system is influenced by the surrounding hormonal milieu. The CNS monitors the existin~ 
endocrine state and alters the firin~ rates of LHRH neurons within the preoptico- 
hypothalamus. 
LHRH NEURON NEUROTRANSMITTERS 
What is the neuropharmacologic basis for transduction of endocrine to 
neurophysiological information at the level of the hypothalamus? The hypothalamus 
contains significant concentrations of a variety of neurotransmitters including, dopamine, 
norepinephrine and epinephrine (17-19). Further, dense concentrations of adrener~,ic 
receptor sites are located within the preoptico-hypothalamus (20-23). These transmitter 
systems are influenced by the surroundin~ endocrine environment. Gonadal steroids 
alter the concentration and turnover rates of many neurotransmitters and their receptors 
in the CNS and elsewhere (15-17,24-26). Hormonally modulated chan~es in the activitv 
of tyrosine hydroxylase (the rate limiting, enzyme in catecholamine biosynthesis; 27) 
and monoamine oxidase (28) have also been demonstrated. Althou~h the hypothalamus 
is rich in catecholaminer~,ic activity, most (80%) of these neurotransmitters are 
synthesized by extrahypothalamic neurons (29,30). Noradrener~ic cell bodies located 
in the lateral tegmentum nucleus, tractus solitarius and dorsal motor nucleus of vagus 
project to the preoptico-hypothalamus via the ventral te~,mental pathway and the medial 
forebrain bundle and innervate virtually all hypothalamic nuclei (29,31). These midbrain 
catecholaminergic cell bodies have been shown to regulate LHRH release in rats (32,33). 
Further support for a role of midbrain catecholaminer~ic neurons in the control of 
reproductive processes is provided by the observation that 40-80% concentrate estradiol 
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(34). Neurons that concentrate 3H-estradiol have also been identified within the 
preoptic area, anterior hypothalamic area, arcuate nucleus and median eminence (12). 
Many hypothalamic neurons that concentrate estrad{ol also stain positively for tyrosine 
hydroxylase (35). Thus, ample neuroanatomical evidence exists to implicate 
extrahypothalamic catecholaminergic neurons in the regulation of pulsatile discharges 
of hypothalamic LHRH. Furthermore, disruption or reduction in ~ adrener~ic 
neurotransmission by o methyl-p-tyrosine injection (36), reserpine treatment (37), 
adrenergic receptor blockade (38), or opiate administration (39) (to reduce 
catecholaminer~ic turnover) inhibits pulsatile LH secretion in castrate animals or blocks 
estradiol-induced LH surge releases. An o adrenergic link in the activation of the 
LHRH neuron is also supported by studies in which norepinephrine or epinephrine, 
injected into the Ill ventricle of estradiol-primed rats, causes a release of pituitary 
LH (40-42). Estradiol-induced increases in hypothalamic LHRH release (43) and pituitary 
LH discharges (44) may be blocked by injections of phenoxybenzamine or prazosin, ° l  
adrenergic receptor blockin{~ agents. At the level of the median eminence, ~2 
adrenoreceptors are most prevalent (21-23). Combined, this information suggests that 
a multi-synaptic, o adrenergic neuronal network is involved in the transduction of 
gonadal steroid to electrical to neurohumoral information. Extrahypothalamic and 
hypothalamic neurons monitor circulating levels of ~,onadal steroids (estradiol) and 
dictate (through alpha adrener~fic neurotransmission) the frequency of pulsatile 
discharges of LHRH from hypothalamic neurons and therefore the release of 
gonadotropins from the pituitary. 
In addition to modulation of LHRH pulse frequency, gonadal steroids appear to 
determine whether a neurophysiological or neuropharmacolo~'ical manipulation of a 
particular brain region will stimulate or inhibit pituitary LH release. Electrical 
stimulation of the mesencephalic noradrenergic pathway in ovariectomized (ovx) rats 
results in the suppression of LH pulses (45). Stimulation of this same area in steroid- 
primed, ovx animals fails to suppress LH pulses. A similar finding has been reported 
with stimulation of the arcuate nucleus within the hypothalamus (46). Further, injections 
of NE into the third ventricle of ovx rats suppresses LH pulsatility while a similar 
injection in steroid-primed animals causes a release of LH (40,42,47). Effects of such 
treatments upon pituitary FSH secretion have not been reported. Examination of the 
influence of a neuropharmacolo~,ic manipulation or a neurally active dru~f must be 
carefully controlled with regard to steroid milieu. Opposite effects may be elicited 
in test subjects exposed to identical treatments during different reproductive states 
or simply by the injection of estradiol. In spite of information available about the 
effects of ~onadal hormones upon a variety of neurophvsiolo~fical and 
neuropharmacological parameters, our understanding of the neurotransmitter systems 
that regulate LH and especially FSH release throu~fh the secretion of hypothalamic 
LHRH is incomplete. 
INTERPRETATION OF NEUROPHARMACOLOGIC STUDIES 
Many studies that have attempted to determine the neuropharmacologic factors 
involved in the regulation of gonadotropin release have been contradictory. A variety 
of drugs have been injected into test animals and the effect upon ~,onadotropin release 
has been monitored. Many of the neurochemicals tested lacked receptor specificity. 
These substances may have served as precursors to other neurotransmitters (i.e., infused 
dopamine or norepinephl'ine being converted to norepinephrine or epinephrine). Thus, 
if dopamine is infused into the CNS, it cannot be determined if changes in gonadotropin 
secretion are due to activation of dopaminergic or noradrenergic systems. Another 
source of confusion has been the lack of knowled~fe of the effects of dru~s at the 
receptor site. Initially, adrenergic receptors were classified according, to their location. 
Alpha I adrenoreceptors were thou~fht to be localized postsynaptically and o 2 receptors 
were hypothesized to be presynaptic autoreceptors (48-51). These receptors exhibit 
different affinities for specific neuropharmacolo{~ic a~fents. For instance, clonidine, 
an adrenergic agonist, binds with much ~freater affinity to n 2 receptors. Hypothetically, 
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activation of these presynaptic receptors with clonidine would decrease endogenous 
neurotransmitter release. Norepinephrine exhibits equal affinities for ~I and 2 receptors. 
Phenylephrine exhibits a preferential affinity for ~I receptors. Shortly after it was 
proposed, the hypothesis was refuted that anatomical location was the basis upon which 
"I and c~ 2 adrenoreceptors were segregated (20). Destruction of presynaptic terminals 
by injection of 6-OH dopamine or lesions of noradrener~ic cell bodies was not 
accompanied by a rapid decline in ~2 binding, in spite of the degeneration of presynaptic 
neurons. It is now well accepted that ~I and "2 receptors are present postsynapticallv 
(52). Although the physiologic role of presynaptic receptors is in question (53), it has 
been demonstrated that activation of putative presynaptic autoreceptors by - al~onists 
reduces neurotransmitter release (51,53). Saturation of presynaptic receptors with 
antagonists actually increases endogenous neurotransmitter release (55). The preoptico- 
hypothalamus contains c~ I and c~ 2 receptors, with the latter preferentiallv located in 
the arcuate-median eminence region (21-23). Thus, conflictinl~ reports of hormonal 
responses to neuropharmacolo~ic manipulation may be due not only to the lack of 
specificity of the drug, but a presynaptic effect of the drug as well.  Furthermore, 
a variety of other neurotransmitters have been reported to affect the LHRH neuron 
directly, or indirectly by an influence upon the activity of catecholaminergic neurons 
(15,16). Receptors for many other neurotransmitter systems are heterogeneous, both 
in ligand binding and post-receptor events (56-61). Great care must be exerted in the 
execution and interpretation of neuroendocrine experiments performed with all 
neurotransmitter agonists and antagonists. 
FSH VS LH REGULATION 
In addition to the problems that surround the study of the neuropharmacologic 
control of the LHRH neuron, another dilemma exists. Many investil~ators have Dresented 
evidence that the neuroendocrine mechanisms that regulate LB and FSH are dissimilar 
(62-69). For instance, disruption of cv adrenergic neurotransmission by the injection 
of drugs that affect catecholamine biosynthesis (62) or turnover (64) results in a rapid 
diminution in LH but not FSH pulse frequency. Further, alterations in the rate of 
pituitary LII secretion are accompanied by chan~,es in catecholamine turnover within 
specific hypothalamic nuclei (16). Alterations in the rate of pituitary FSH secretion 
are not accompanied by changes in hypothalamic catecholamine content (70,71). The 
neurotransmitter systems that influence the release of pituitary FSH are unknown. 
Although little is known about the neuroendocrine mechanisms that regulate FSB 
secretion, it is apparent that the release of this ~'onadotropin is regulated by neural 
mechanisms. Pulsatile FSH release is not observed from pituitary tissue in vitro (72). 
Stalk sections or total ablation of the arcuate-median eminence re~ion does not result 
in continued FSH release (6,7). Electrical stimulation of CNS ref~ions (apart from those 
that regulate LH release) results in a selective release of FSH (73). Ablation (74), 
implantation of prostaglandins (75) and deafferentation (76,77) studies support the 
hypothesis that a separate neural re~ion regulates FSH secretion. 
As mentioned above, the frequency of LNRH pulse releases influences the relative 
proportions of LH and FSH released. However, recent studies su~,est that many of 
the elevations in FSH secretions cannot be explained on the basis of alterations in 
LHRH pulse frequency. Indeed, a controversy exists as to the involvement of LI-IRH 
in the release of FSH. Immunoneutralization of LHRN (62,66,78) or iniection of LHRH 
antaRonists (79,80) exerts dramatic effects upon LH pulsatility in serum while not 
affecting FSH. Contrary to these findings, increases in pituitary portal blood 
immunoreactive LHRH concentrations have been observed during times of selective FSH 
releases (during estrus or after ovariectomy) (11,81). Furthermore, data are available 
to suggest that a specific releasing hormone (distinct from LHRH) re~'ulates the release 
of FSH (82,87). Cyclic fluctuations in hypothalamic FSH releasing, activity have been 
observed without changes in LHRR bioactivity (84-87). The neuroanatomica] location 
of neurons that synthesize a putative FSFI releasin~ hormone remains a mvsterv. 
Vol. 36, No. 2, 1985 Neuroendocrine Control of LH and FSH i01 
Thus, the reproductive neuroendocrine system ~)rovides a unique model that may 
be employed to study the interaction between gonadal steroids, central nervous tissue, 
neurosecretory cells and anterior pituitary hormones. Research efforts in reproductive 
neuroendocrinology have elucidated the mechanisms that regulate the release of pituitary 
LB. Progress in our understanding of the neural regulation of FSH secretion is occurrin~ 
at a much slower rate. Information about the interactions between ~onadal steroids, 
nervous tissue, neurotransmitter systems and the hyoothalamic LBRH neuron is 
accumulating steadily. With the availability of refined techniques such as neural 
microdissection methods, specific neuroDharmacolo~ic agonists and antagonists, single 
unit neural recordings and immunohistochemistry, the gaps and inconsistencies that 
presently exist will be overcome. 
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